Related Experiment Video
Updated: Feb 16, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Clinical trials and biomarker development with molecularly targeted agents and radiotherapy
1Princess Margaret Hospital, Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Introduction:
The conventional paradigm of drug development used for cytotoxic chemotherapeutic agents may not represent the most effective method of assessing the safety and biological activity of molecularly targeted agents, given that the latter may offer improved therapeutic indices with less toxic effects on normal tissues.
Objectives:
With the number of novel therapeutics in oncology entering the investigative arena, there is a need to expedite the drug development process by allowing for optimal selection of agents with the greatest likelihood of having clinical benefit over those of lower potential utility.
Discussion:
The high throughput techniques now available in genomic, proteomic and metabolomic profiling should allow for more effective preclinical investigation with the identification of biomarkers or indicators of treatment response, leading to increased clinical efficacy with appropriate patient selection.
Conclusion:
With this in mind, current investigation should be directed at validating novel endpoints in order to accelerate the drug development and approval process with targeted therapeutics in oncology.
Insights
Conventional drug development models may not suit targeted cancer therapies. Utilizing genomic and proteomic profiling can accelerate the development of effective oncology treatments by identifying biomarkers for patient selection and improved clinical efficacy.
Area of Science:
- Oncology
- Pharmacology
- Biomarker Discovery
Background:
- Traditional cytotoxic chemotherapy drug development paradigms may be suboptimal for molecularly targeted agents.
- Targeted agents often exhibit improved therapeutic indices and reduced toxicity to normal tissues compared to conventional chemotherapeutics.
Purpose of the Study:
- To address the need for expedited drug development in oncology for novel therapeutics.
- To optimize the selection of investigational agents with higher potential for clinical benefit.
Main Methods:
- Leveraging high-throughput genomic, proteomic, and metabolomic profiling techniques.
- Identifying biomarkers or indicators of treatment response through advanced profiling.
Main Results:
- Preclinical investigations can be made more effective through advanced profiling.
- Biomarker identification facilitates better patient selection and treatment response prediction.
Conclusions:
- High-throughput profiling enables more efficient preclinical evaluation of targeted oncology therapeutics.
- Validating novel endpoints is crucial for accelerating the drug development and approval process for targeted therapies in oncology.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
Molecular Models
Molecular Orbital Theory II

